TMCnet News
Global Autoimmune Disease Diagnostics Market to Witness Growth Through 2021, Due to the Worldwide Rise in the Incidence of Autoimmune Diseases: TechnavioTechnavio analysts forecast the global autoimmune disease diagnostics market to grow at a CAGR of more than 6% during the forecast period, according to their latest report. The research study covers the present scenario and growth prospects of the global autoimmune disease diagnostics market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of various diagnostic tests for autoimmune diseases to key end-users such as hospitals, central laboratories, and physicians' office laboratories. The growing consolidation in autoimmune disease diagnostics market is expected to increase technology transfer between companies, thereby fueling the availability of robust diagnostic systems. For instance, Sengenics acquired Oxford Gene Technology's protein array technology, which finds use in the diagnosis of various autoimmune conditions, in 2015. Request a sample report: http://www.technavio.com/request-a-sample?report=53809 Technavio's sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more. Technavio healthcare and life sciences analysts highlight the following three factors that are contributing to the growth of the global autoimmune disease diagnostics market:
Discovery of novel biomarkers leading to improved autoimmune diagnosis The development of novel biomarker has resulted in the improvement in the diagnosis of autoimmune diseases. Individuals with autoimmune diseases can develop multiple symptoms, which can be tough for physicians to diagnose. The use of singular conventional biomarkers proved to be of little help and limited reproducibility for laboratory personnel. Therefore, there is an increased demand for multiple biomarkers that could help identify and evaluate the patient statu, disease type, and progression and response to therapy for autoimmune diseases. According to Barath Palada, a lead analyst at Technavio for in-vitro diagnostics research, "The ability to screen an individual with multiple biomarkers associated with several autoimmune diseases has improved the positive diagnosis. Moreover, it has substantially influenced the autoimmune disease diagnostics market and would continue to prove to be an added advantage for physicians in the diagnosis of such complications." Advancements in laboratory automation platforms The incidence of autoimmune diseases is rising worldwide, which is increasing the volume of samples being collected for analysis. This has led to the demand for automation in autoimmune disease diagnostics for rapid analysis and interpretation of results. Automation involves a series of integrated steps that include pre-analytical and post-analytical stages to help minimize the need for manual intervention and thus avoid errors. "Most central laboratories engage in automation, as they conduct a large-scale analysis of samples," says Barath. Vendors such as Abbott Laboratories, Beckman Coulter, Siemens (News - Alert) Healthcare, and Inova Diagnostics are offering automated systems to central and medium-sized laboratories for sample analysis. Some of these systems are available as stand-alone or integrated analyzers, which are capable of assessing various assays apart from autoimmune diagnostic assays. This has increased the number of laboratories that obtain these systems for routine diagnostic analysis. Increasing M&A The increasing number of consolidations within the market allows technology exchange leading to the development of robust immunoassay systems. The autoimmune disease diagnostics market has been witnessing a number of industrial consolidations. The major emphasis for such consolidations can be partly attributed to the manufacturers' intention to expand their portfolio and to incorporate and integrate technology with existing platforms and assays. As a part of such consolidations, manufacturers engage in technology sharing that has led to the introduction of many successful, robust automated immunoassay platforms, which are becoming a trend for manufacturers to attract a wide customer base. For example, in 2015, Sengenics acquired Oxford Gene Technology's protein array technology, a patented autoantibody profiling platform, which finds use in diagnosing various diseases including autoimmune conditions. Also, the acquisition will strengthen the company's foothold in the proteomics market and offer its customers added flexibility to leverage this technology to model the immune system. Browse Related Reports:
Do you need a report on a market in a specific geographical cluster or country but can't find what you're looking for? Don't worry, Technavio also takes client requests. Please contact [email protected] with your requirements and our analysts will be happy to create a customized report just for you. About Technavio Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies. Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users. If you are interested in more information, please contact our media team at [email protected]. View source version on businesswire.com: http://www.businesswire.com/news/home/20161024006374/en/ |
